Edison issues update on NetScientific (NSCI)


LONDON, Oct. 19, 2018 (GLOBE NEWSWIRE) -- NetScientific (NSCI) recently announced half-year results for 2018, with incremental progress continuing to be made, although we are yet to see that progress in reported revenues. In May 2018, Wanda, which focuses on digital health, and its partner Health Resource Solutions (HRS), achieved a 46% reduction in hospital readmissions in a high-risk congestive heart failure (CHF) population. In addition, in August ProAxsis announced a CE Mark for a fourth product, the ProteaseTag Active Proteinase 3 immunoassay, which was accompanied by a commercial sale to a large US biotechnology company.

We have reduced our valuation of NetScientific to £50.6m or 64p per share from £67.9m or 86p per share. This is mainly due to a more conservative view of the revenue ramp for ProAxsis, Vortex, Wanda and Glycotest (although peak sales remain the same), as reported revenues were trending lower than anticipated, as well as a lower cash balance. This was partly mitigated by rolling forward our NPVs.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website
www.edisoninvestmentresearch.com

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Maxim Jacobs, +1 646 653 7027
Nathaniel Calloway, +1 646 653 7036
healthcare@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 
LinkedIn   https://www.linkedin.com/company/edison-investment-research
Twitter     www.twitter.com/Edison_Inv_Res
YouTube   www.youtube.com/edisonitv